Sugi Predict

Sugi Predict / Compounds / SCHEMBL21530639

SCHEMBL21530639

SCHEMBL21530639

CCCCCn1c2cc(Br)n(S(=O)(=O)c3ccccc3)c2c(=O)n2c(C)nnc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 8/20 0.50
▸ BRD4 O60885 2/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ CCR3 P51677 1/20 0.35
▸ HTT P42858 2/20 0.34
▸ TP53 P04637 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ PLK1 P53350 1/20 0.34
▸ APOBEC3G Q9HC16 1/20 0.34
▸ AGTR1 P30556 1/20 0.33
▸ PDE4A P27815 1/20 0.33
▸ PDE4B Q07343 1/20 0.33
▸ PDE4C Q08493 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ CNOT7 Q9UIV1 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ GLA P06280 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21530650 0.87 ALDH1A1 (0.38) ADORA2ABRD4ALDH1A1SMN1; SMN2HTT
SCHEMBL21530664 0.82 ADORA2A (0.56) ADORA2ABRD4ALDH1A1SMN1; SMN2CCR3
SCHEMBL21530680 0.69 ADORA2A (0.42) ADORA2ABRD4ALDH1A1SMN1; SMN2HTT
SCHEMBL21530708 0.69 ADORA2A (0.65) ADORA2AALDH1A1SMN1; SMN2PLK1APOBEC3G
SCHEMBL21530720 0.67 ADORA2A (1.00) ADORA2AALDH1A1SMN1; SMN2PLK1APOBEC3G
SCHEMBL21530648 0.67 ADORA2A (1.00) ADORA2ABRD4ALDH1A1SMN1; SMN2CCR3
SCHEMBL21530640 0.65 ADORA2A (1.00) ADORA2AALDH1A1SMN1; SMN2TSHR
SCHEMBL561761 0.63 ADORA2A (0.63) ADORA2AALDH1A1TSHRMAPK1CYP1A2
SCHEMBL25572314 0.63 TDP1 (0.46) ALDH1A1SMN1; SMN2HTTTP53TSHR
SCHEMBL21530645 0.62 ADORA2A (1.00) ADORA2AALDH1A1SMN1; SMN2PLK1APOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115279766-B Combination therapy comprising A2A/A2B and a PD-1/PD-L1 inhibitor 因赛特公司 2025-05-02 — — CN disclosed
US-20250059293-A1 CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY INCYTE CORPORATION 2025-02-20 — — US disclosed
US-20250041310-A1 Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors INCYTE CORPORATION 2025-02-06 — — US disclosed
US-12060433-B2 CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy INCYTE CORPORATION (US) 2024-08-13 — — US disclosed
CN-117500503-A Combination therapy comprising an A2A/A2B inhibitor, a PD-1/PD-L1 inhibitor and an anti-CD 73 antibody 因赛特公司 2024-02-02 — — CN disclosed
EP-4271384-A1 COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIBITORS, AND ANTI-CD73 ANTIBODIES Incyte Corporation (US) 2023-11-08 — — EP disclosed
CN-115551595-A Combination therapy of a CD73 inhibitor and an A2A/A2B adenosine receptor inhibitor 因赛特公司 2022-12-30 — — CN disclosed
EP-4084870-A1 CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY Incyte Corporation (US) 2022-11-09 — — EP disclosed
EP-4085060-A1 COMBINATION THERAPY COMPRISING A2A/A2B AND PD-1/PD-L1 INHIBITORS Incyte Corporation (US) 2022-11-09 — — EP disclosed
CN-115279766-A Combination therapy comprising A2A/A2B and PD-1/PD-L1 inhibitors 因赛特公司 2022-11-01 — — CN disclosed
US-20210230294-A1 CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY INCYTE CORPORATION 2021-07-29 — — US disclosed
US-20210230294-A1 CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY INCYTE CORPORATION 2021-07-29 — — US disclosed
WO-2021138498-A1 CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY INCYTE CORPORATION (US) 2021-07-08 — — WO disclosed
WO-2021138498-A1 CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY INCYTE CORPORATION (US) 2021-07-08 — — WO disclosed
WO-2021138512-A1 COMBINATION THERAPY COMPRISING A2A/A2B AND PD-1/PD-L1 INHIBITORS INCYTE CORPORATION (US) 2021-07-08 — — WO disclosed
WO-2021138512-A1 COMBINATION THERAPY COMPRISING A2A/A2B AND PD-1/PD-L1 INHIBITORS INCYTE CORPORATION (US) 2021-07-08 — — WO disclosed
US-20210205311-A1 Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors INCYTE CORPORATION 2021-07-08 — — US disclosed
US-20210205311-A1 Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors INCYTE CORPORATION 2021-07-08 — — US disclosed
US-20190337957-A1 PYRROLE TRICYCLIC COMPOUNDS AS A2A / A2B INHIBITORS INCYTE CORPORATION 2019-11-07 — — US disclosed
US-20190337957-A1 PYRROLE TRICYCLIC COMPOUNDS AS A2A / A2B INHIBITORS INCYTE CORPORATION 2019-11-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12060433-B2 CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy ADORA2A, ADORA2B, NT5E ADORA2A 1/4885BRD4 1902/4885ALDH1A1 565/4885
US-20250059293-A1 CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY ADORA2A, ADORA2B, NT5E ADORA2A 1/4885BRD4 1902/4885ALDH1A1 565/4885
US-20190337957-A1 PYRROLE TRICYCLIC COMPOUNDS AS A2A / A2B INHIBITORS ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885BRD4 2414/4885ALDH1A1 1049/4885
US-20250041310-A1 Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885BRD4 1079/4885ALDH1A1 187/4885
US-20210230294-A1 CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY ADORA2A, ADORA2B, NT5E ADORA2A 1/4885BRD4 1902/4885ALDH1A1 565/4885
US-20210205311-A1 Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885BRD4 1079/4885ALDH1A1 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.